ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

  1. Ocio, E.M.
  2. Efebera, Y.A.
  3. Hájek, R.
  4. Straub, J.
  5. Maisnar, V.
  6. Eveillard, J.-R.
  7. Karlin, L.
  8. Mateos, M.-V.
  9. Oriol, A.
  10. Ribrag, V.
  11. Richardson, P.G.
  12. Norin, S.
  13. Obermüller, J.
  14. Bakker, N.A.
  15. Pour, L.
Revue:
Haematologica

ISSN: 1592-8721,  0390-6078

Année de publication: 2024

Volumen: 109

Número: 3

Pages: 867-876

Type: Article

DOI: 10.3324/HAEMATOL.2023.283490 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus